628711-07-9

Upstream product

• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 628711-09-1 ethyl 4-benzyloxy-3-(4-methoxyphenyl)benzoate 
• 628711-08-0 benzyl 4-benzyloxy-3-(4-methoxyphenyl)benzoate 
• 1042333-73-2 benzyl 4-(benzyloxy)-3-cyanobenzoate 
• 1191280-72-4 (R)-3-(2-(benzyloxy)-5-(benzyloxy(methyl-d2))phenyl)-N,N-di(isopropyl-d7)-3-phenylpropanamide 
• 1191280-73-5 (R)-3-(2-(benzyloxy)-5-(benzyloxy(methyl-d2))phenyl)-N,N-di(isopropyl-d7)-3-phenylpropan-1-amine 
• 1191280-62-2 (R)-3-(2-(benzyloxy)-5-(benzyloxymethyl)phenyl)-N,N-di(isopropyl-d7)-3-phenylpropanamide 
• 1191280-63-3 (R)-3-(2-(benzyloxy)-5-(benzyloxymethyl)phenyl)-N,N-di(isopropyl-d7)-3-phenylpropan-1-amine 
• 1191280-74-6 (R)-2-(3-(di(isopropyl-d7)-amino)-1-phenylpropyl)-4-(hydroxyl(methyl-d2))phenyl isobutyrate 
• 1191280-66-6 (R)-3-((R)-3-(2-(benzyloxy)-5-(benzyloxy(methyl-d2))phenyl)-3-phenylpropanoyl)-4-phenyloxazolidin-2-one 
• 1191280-59-7 (R)-3-((R)-3-(2-(benzyloxy)-5-(benzyloxymethyl)phenyl)-3-phenylpropanoyl)-4-phenyloxazolidin-2-one 
• 1191280-71-3 (R)-2-(3-(di(isopropyl-d7)-amino)-1-phenylpropyl)-4-(hydroxyl(methyl-d2))phenol 
• 1191280-58-6 (R)-2-(3-(di(isopropyl-d7)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenol 
• 1191280-69-9 (R)-3-(2-(benzyloxy)-5-(benzyloxy(methyl-d2))phenyl)-N,N-diisopropyl-3-phenylpropanamide 
• 1191280-70-2 (R)-3-(2-(benzyloxy)-5-(benzyloxymethyl-d2)phenyl)-N,N-diisopropyl-3-phenylpropan-1-amine 

Relevant academic research and scientific papers

Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5

Based on SAR in the alkyne class of mGlu5 receptor negative allosteric modulators and a set of amide-based positive allosteric modulators, optimized substitution of the aryl bring was used to create substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides.

Structure-activity relationships comparing N-(6-methylpyridin-yl)- substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists

The metabotropic glutamate receptor subtype 5 (mGluR5) has been implicated in anxiety, depression, pain, mental retardation, and addiction. The potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP, 1) has been a critically important tool used to further elucidate the role of mGluR5 in these CNS disorders. In an effort to provide novel and structurally diverse selective mGluR5 antagonists, we previously described a set of analogues with moderate activity wherein the alkyne bond was replaced with an amide group. In the present report, extended series of both amide and alkyne-based ligands were synthesized. MGluR5 binding and functional data were obtained that identified (1) several novel alkynes with comparable affinities to 1 at mGluR5 (e.g., 10 and 20-23), but (2) most structural variations to the amide template were not well tolerated, although a few potent amides were discovered (e.g., 55 and 56). Several of these novel analogues show drug-like physical properties (e.g., cLogP range = 2-5) that support their use for in vivo investigation into the role of mGluR5 in CNS disorders.

DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF

This invention relates to novel derivatives of tolterodine, 5-hydroxymethyl tolterodine, fesoterodine and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such comp

MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 AND USES THEREOF

Disclosed are compounds and pharmaceutically acceptable salts, which are modulators of the metabotropic glutamate receptor 5, for use in treating drug abuse and other mental disorders, for example, a compound of Formula (I), wherein X, Y, and R1/sup

CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES

The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.